FDAsafety guidance66% confidence
GDUFA III Drug Master File (DMF) Review Enhancements
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for ACADIA Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Effective communication among ANDA applicants, DMF holders, and FDA is essential for reducing the likelihood of potential problems that could delay approvals.
Supporting Context
- Therapeutic area
- Neurology · Parkinson's Disease
- Sub-indication
- General
Related signal: FDA grants priority review for NUPLAZID supplemental application